Biochemistry in Relation to Dermatology in The Past 25 Years  by Lerner, Aaron B.
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, 67 :70-71, 1976 
Copyright © 1976 by The Williams & Wilkins Co. 
Vol. 67, No.1 
Printed in U.S.A. 
BIOCHEMISTRY IN RELATION TO DERMATOLOGY IN THE PAST 25 YEARS 
AARON B. LERNER, M.D. 
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, U. S. A. 
Great progress has been made during the past 25 years in biochemical studies and similar 
progress has been made in investigative dermatology. The progress originally depended upon 
the development of a group of leaders who won support for research endeavors, and in the 
future its continuation will depend upon support for basic research in clinical departments. 
Current studies on melanocyte-stimulating hormone receptors, the role of filaments in 
pigment cells, and the role of cyclic AMP in melanocytes are reviewed. 
I have been in dermatology a little over 25 years 
and was in chemistry and biochemistry for several 
years before that. Here I wish to summarize the 
status of biochemistry at that time and the kinds of 
support for research given by the leading der-
matologists. Twenty-five years ago scientists were 
working in many different fields of biochemistry 
and biology, but the major attractions were pro-
teins, enzymes, coenzymes, lipids, carbohydrates, 
intermediary metabolism, and energy metabolism. 
The use of electrophoresis, ultracentrifugation, 
and isotopes-heavy and radioactive-had just 
begun. Chemists were generally reluctant to be-
come involved with large molecules. Peptide hor-
mones from the pituitary gland, insulin from the 
pancreas, proteins, and nucleic acids of all kinds 
were considered by many to be too . large and 
complicated for any reputable chemist to study 
seriously . My excellent teacher in protein and 
colloid chemistry, Ross Gortner, stated repeatedly 
that no one had been able to purify a protein from 
blood and that the amino acid composition of any 
protein was not known. My own stimulus as a 
graduate student to work on a cryoglobulin was 
related as much to being able to prepare a protein 
from blood in a homogeneous form as it was to 
discover a relation between the physical properties 
of the cryoglobulin and the symptoms of the 
patient. 
The situation in dermatology was the same as 
that in all medical specialties. Most of the research 
was applied; little effort was made to engage in 
basic research that would provide a firm basis for 
studying the nature of various diseases at a level 
that would be usef~l in the future. In our specialty, 
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the well-known dermatologists were well known 
precisely because of their successes in studying 
infectious diseases such as venereal disorders, 
tuberculosis, and mycotic infections or because of 
their accomplishments in dermatopathology. The 
leaders in dermatology had neither background, 
resources, nor the inclination to engage in basic 
studies. There were three exceptions. Donald Pills-
bury succeeded in getting funds from the NIH for 
research in dermatology. True, others had paved 
the way and might have been equally suc.cessful, 
but I believe that Pillsbury deserves the major 
credit for interesting the NIH in dermatologic 
research. Arthur Curtis, an outstanding teacher in 
physical diagnosis as well as an excellent clinician, 
did no basic research himself, but he had personal-
ity and the astuteness to win support for basic 
research. Unlike some other outstanding clinicians 
and pathologists who have or had a fear of re-
search, Curtis entertained no such apprehensions. 
The third outstanding leader was Stephen Roth-
man, who wanted to be and was an active partici-
pant in biochemical research. 
Despite many failures, waste of money, and lost 
time spent on unworthy projects, the advance-
ments during the past 25 years have been almost 
too numerous to mention: the development of 
molecular biology and of better methods for sepa-
rating large molecules and parts of cells; the use of 
x-ray diffraction to study macromolecules; the 
discovery of hormonal function; the determination 
of the primary, secondary, tertiary, and quaternary 
structures of proteins and nucleic acids and of the 
ultrastructure of cells; perfecting computer dis-
plays of parts of cells in three dimensions; identify-
ing the properties of receptors on cells; and under-
standing the structure of membranes. All of these 
advances made their impact on every aspect of 
medicine. In dermatology specifically, these ad-
vances have improved our knowledge of keratin, 
connective tissue, melanin pigmentation, photobi-
ology, and immunology. 
Because the methods of the physical and biologic 
sciences are now so powerful, the community of 
scientists, together with the funding agencies, have 
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:;ome important decisions to make. Should the 
Drimary, secondary, tertiary, and quaternary 
:;tructures of superoxide desmutase, tyrosinase, 
i)hosphodiesterase, or some other enzyme be deter-
mined? Should a major effort be made to learn why 
adenylate cyclase cannot be isolated by procedures 
that have been used so successfully for other 
enzymes? How much more time and money should 
be spent studying the etiology and cure of cancer or 
the process of aging? Whatever the decision, step 
by basic step, these phenomena will, at the molec-
ular level, yield their secrets. 
Our current dilemma is how much time does one 
spend being an investigator, how much being a 
clinician. To do good research in the medical 
sciences, one must devote an enormous amount of 
time, maybe too much to have any left over for 
clinical medicine. Yet the need for both has 
increased. Advances in medical science presuppose 
that some kind of support for effective basic 
research will be given by the clinical departments 
of all medical schools. 
So much for the past. Currently, biochemists 
and dermatologists are collaborating on several 
important areas of research with pigment cells. 
One has to do with receptors for melanocyte-
stimulating hormones (MSH) on melanocytes, the 
other with the reiation between 100 A filaments 
and microtubules in pigment cells. The use of 1251 
or fluorescein-labeled hormone has made it possi-
ble to visualize on melanocytes the general location 
of receptors for MSH [1,2]. Such experiments, 
though technically possible for many years, were 
not done until people realized that peptide hor-
mones work by activating adenylate cyclase on the 
plasma membrane of cells. In addition, using 
immunofluorescence techniques we can now show 
that the activation of adenyl ate cyclase leads to an 
increase in fixed 3' ,5' -cyclic adenosine monophos-
phate (cAMP) within the cells [2,3]. 
From our studies with dark and light melano-
cytes from frogs, we know that when melanosomes 
are dispersed throughout the cells, there is an 
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abundance of 100 A filaments. When the cells are 
light, the granules aggregate near the nuclei, and 
microtubules predominate [4,5]. From experi-
ments of this kind, we have been able to show the 
relation between 100 A filaments and microtubules. 
That is, for the formation and removal of tubules 
and 100 A filaments there is a reversible reaction 
which is controlled by the level of cAMP within 
the cell. This level, in turn is controlled by the ac-
tivities of adenylate cyclase on the plasma mem-
brane to produce cAMP and of phophodiesterase 
within the cytoplasm to catalyze the hydrolysis of 
cAMP. 
In melanoma cells from mammals, we know that 
cAMP formed by the influence of MSB on adenyl-
ate cyclase activates preexisting molecules of tyro-
sinase. These changes, in turn, affect the length of 
the cell cycle of malignant melanocytes (R. Bala-
ban, A. B. Lerner, unpublished data). 
Work like this, i.e., studies on one kind of cell 
from different animals, will eventually tell us how 
normal cells function and what changes they 
undergo when they age or become malignant. 
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